Advanced in Teratoma of the Mediastinum

Jonathan Shamash

St Bartholomew's Hospital, W Smithfield, 
London, ENG, GB 
Advanced in Teratoma of the Mediastinum
St Bartholomew's Hospital, W Smithfield, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Jonathan Shamash practices in London, United Kingdom. Mr. Shamash is rated as an Advanced expert by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Testicular Cancer, Teratoma of the Mediastinum, Prostate Cancer, Orchiectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 92 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles and participated in 1 clinical trial in the study of Teratoma of the Mediastinum.

Gender
Male

Locations

St Bartholomew's Hospital, W Smithfield, London, ENG EC1A7BE, United Kingdom
Other Locations
Barking, ENG, United Kingdom
Mount Vernon Cancer Centre
Northwood, ENG HA62RN, United Kingdom
United Kingdom
St Bartholomew's Hospital, 7th Floor, Gloucester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis
A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis
Enrollment Status: Completed
Publish Date: June 14, 2024
Intervention Type: Drug
Study Drugs: Filgrastim, Actinomycin D, Methotrexate, Paclitaxel, Oxaliplatin
Study Phase: Phase 2
A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT
A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT
Enrollment Status: Completed
Publish Date: January 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

92 Total Publications

Therapy de-escalation for testicular cancer (THERATEST): A multi-centre observational cohort feasibility study of de-escalation therapies for good prognosis stage II germ cell tumours.
Therapy de-escalation for testicular cancer (THERATEST): A multi-centre observational cohort feasibility study of de-escalation therapies for good prognosis stage II germ cell tumours.
Journal: BJUI compass
Published: June 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Shamash's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile